From Normal Variation in Sleep to Clinical Sleep Disorders: Genetic Insights from Over One Million Individuals - Kunorozva, Lovemore; Valliere, Jesse; Chen, Chia-Yen; Maher, Matthew; Tchio, Cynthia; Burns, Angus; Zhang, Yingzhe; Strausz, Satu; FinnGen; Estonian Biobank Research Team; Winkelman, John; Gottlieb, Daniel J; et al. (medRxiv, 2025)
Sleep disorders affect over 30% of the U.S population and are linked to increased disease risk and mortality. However, the genetic architecture of sleep disorders and the overlap of sleep disorders with habitual sleep quality, quantity, and timing have been poorly characterized. In addition, it is unknown if clinical sleep disorders are extremes of habitual sleep traits. Here, we systematically investigated the genetic basis of seven clinical sleep disorder traits, and sixteen medications used for sleep problems in 1,600,000 individuals. We identified 590 genetic associations for sleep apnea, insomnia, restless legs syndrome, narcolepsy and a combined sleep disorder phenotype, of which 367 were previously unreported. Additionally, we discovered 142 genetic associations with sleep medication use. While overall genetic architecture was shared across sleep traits, we found unique genetic factors for the different sleep disorders that reflect fundamentally different biological mechanisms including for example autoimmune processes with narcolepsy and skeletal morphology in sleep apnea. Furthermore, sleep genetic factors showed a broad multi-omic impact on gene and protein expression levels. These findings suggest that while clinical sleep disorders share genetic architecture with each other and with variation in sleep patterns within the general population, they are not simply extremes of normal sleep variation but involve unique biological mechanisms. These results advance our understanding of sleep disorders and suggest potential novel therapeutic targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the NIH grants R35 GM146839 (J.M.L), R01 HG012810 (J.M.L; H.M.O), R01 AI170850 (R.S.; H.M.O.) and R01 DK107859 (R.S).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used is from the UK biobank, MGB biobank, Million Veterans Program, FinnGen cohort, All of Us Biobank, and Estonian BiobankI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSummary statistics will be made publicly available upon publication, both as supplementary data with the manuscript and through deposition in the Sleep Disorders Knowledge Portal (SDKP).